Corgenix Medical Corporation, Tulane University, And Viral Hemorrhagic Fever Consortium Publish Promising Results From Lassa Fever Trial

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DENVER--(BUSINESS WIRE)--A Corgenix Medical (OTCBB:CONX) rapid diagnostic test (RDT) for the dangerous Lassa fever virus has demonstrated the ability to quickly detect the virus, responsible for the deaths of thousands and infection of hundreds of thousands in West Africa each year. That’s according to the results of the five-year trial Lassa Fever in Post-Conflict Sierra Leone published in the PLOS Neglected Tropical Diseases Journal.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC